NCT07732166 Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.
| NCT ID | NCT07732166 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Pontifícia Universidade Católica do Rio de Janeiro |
| Condition | Healthy Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 100 participants in total. It began in 2026-04-01 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Self-awareness, the capacity of becoming the object of one's own awareness, is a frontier of scientific knowledge. Over centuries, distinct philosophical and religious traditions have grappled with the subject, but only recently has the importance of self-awareness been established as a central concept for scientific investigation, to which scientific methods can be applied to explore and characterize this phenomenon. Self-awareness has important implications, notably from a clinical perspective. Psychedelics can affect the sense of self, with 'ego dissolution' being an essential feature of the experience of substances such as psilocybin and dimethyltryptamine. Recent evidence indicates that psychedelics can rearrange brain connectivity, with these changes being linked to alterations in self-awareness. Nevertheless, the extent to which specific components of self-awareness are modified by these substances has not been fully explored. It is possible that part of the clinical benefits of psychedelics, for conditions such as depression, OCD, and anxiety, is mediated by changes in self-awareness. Given this clinical potential, the current study aims to examine the effects of psilocybin on various components of self-awareness in healthy participants. 100 participants will be allocated to receive either 15mg of psilocybin (n=50) or an active placebo (100mg niacin; n=50). Participants will be assessed one week before, immediately after, and one week after the administration of the substances, performing tasks and completing questionnaires measuring self-awareness at these time points. The neural correlates of self-awareness, before and after substance effects, will be investigated using near-infrared spectroscopy. Participants allocated to the placebo group will be invited to an open-label extension with psilocybin upon availability of the substance. It is expected that the results of the study will elucidate the brain regions involved in self-awareness, as well as the alterations induced by psilocybin in this process, opening the possibility of new therapeutic interventions for different clinical groups.
Eligibility Criteria
Inclusion Criteria: * Minimum age of 21 and maximum age of 60; * Minimum of eight years of schooling; * Fluency in Portuguese; * Agree, one week before the experiment, to abstain from: * Using any herbal supplements (except with prior approval from the researchers); * Using any non-prescribed medication (except non-steroidal anti-inflammatory drugs or paracetamol, provided they have prior approval from the research team); * Using any prescribed medication (except birth control pills, thyroid hormones, or other medications, provided they have prior approval from the research team); * Using recreational psychoactive substances; * Agree to abstain, 24 hours before the experiment, from: * Consuming beverages with high caffeine content (e.g., coffee, mate, cola); * Consuming alcoholic beverages; * Agreeing not to use caffeine or nicotine for two and six hours, respectively, after the experiment; * Agree not to drive a motor vehicle or operate machinery for 24 hours after the experiment; * Be available to be contacted by telephone for all planned stages; * Agree to use effective contraception throughout the study; * Agree to inform researchers of any medical condition or procedure that may arise prior to the experiment; * Agree not to participate in any other interventional clinical trial for the duration of this study. Exclusion Criteria: * History of traumatic brain injury, stroke, epilepsy, neurological disease, or cardiovascular disease; * Evidence or history of coronary or cerebral artery disease, peripheral vascular disease, liver disease with altered liver enzymes, or any other medical condition that the researchers, including the responsible physician, deem to significantly increase the risk of administering any substance; * Pregnant or breastfeeding women, or women who could potentially become pregnant and are not using any effective contraceptive method; * Women who, at the screening stage, do not have a negative pregnancy test. * Having a history of or currently having a primary psychotic disorder, schizophrenia spectrum disorder, bipolar affective disorder (type 1 and 2), dissociative identity disorder, major depressive disorder; * History of psychotic disorders in a first-degree relative; * Have resting blood pressure that does not exceed 140 mmHg (systolic) and 90 mmHg (diastolic) - measured in four assessments on at least two different days; * Have resting blood pressure below 90 mmHg (systolic) and 60 mmHg (diastolic) - measured in four assessments on at least two different days; * Weigh less than 48 kg; * Require therapy with psychiatric medications concurrently with the study; * Have a history of or present with gastrointestinal disease; * Previous use of psilocybin or similar substances; * Frequent use (at least once a month) of any other psychoactive substance in the last year, except for nicotine, caffeine and alcohol; * Have a history of disorders or problems related to the use of psychoactive substances; * Not be able to provide adequate informed consent; * Any other condition that may compromise the results or that represents any risk to the participant, according to the assessment of the research team and the responsible physician.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07732166 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 60 Years, studying Healthy Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07732166 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07732166 currently recruiting?
Yes, NCT07732166 is actively recruiting participants. Contact the research team at mograbilab@gmail.com for enrollment information.
Where is the NCT07732166 trial being conducted?
This trial is being conducted at Rio de Janeiro, Brazil.
Who is sponsoring the NCT07732166 clinical trial?
NCT07732166 is sponsored by Pontifícia Universidade Católica do Rio de Janeiro. The trial plans to enroll 100 participants.